Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 25.77% is in line with its 5-year average of 28.02%, near the low end of its 5-year range (23.39%–32.97%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.11% below its 12-month average of 26.06%.
Reported quarterly EBITDA margin; no daily interpolation.
EBITDA MARGIN
25.77%
EBITDA MARGIN AVG TTM
26.06%
EBITDA MARGIN AVG 3Y
26.61%
EBITDA MARGIN AVG 5Y
28.02%
EBITDA MARGIN AVG 10Y
25.09%
EBITDA MARGIN AVG 15Y
22.69%
EBITDA MARGIN AVG 20Y
20.78%
CURRENT VS TTM AVG
-1.11%
CURRENT VS 3Y AVG
-3.16%
CURRENT VS 5Y AVG
-8.02%
CURRENT VS 10Y AVG
+2.72%
CURRENT VS 15Y AVG
+13.57%
CURRENT VS 20Y AVG
+24.00%
West Pharmaceutical Services, Inc.
Market Cap
$24.79B
EBITDA Margin
25.77%
TTM Avg
26.06%
3Y Avg
26.61%
5Y Avg
28.02%
Market Cap
$24.48B
EBITDA Margin
27.93%
TTM Avg
16.21%
3Y Avg
17.95%
5Y Avg
14.24%
Market Cap
$25.26B
EBITDA Margin
-147.07%
TTM Avg
-132.24%
3Y Avg
-66.39%
5Y Avg
-46.73%
Market Cap
$26.24B
EBITDA Margin
19.69%
TTM Avg
19.16%
3Y Avg
18.89%
5Y Avg
21.02%
Market Cap
$26.53B
EBITDA Margin
15.75%
TTM Avg
14.53%
3Y Avg
14.10%
5Y Avg
17.90%
Market Cap
$21.72B
EBITDA Margin
50.36%
TTM Avg
50.37%
3Y Avg
51.80%
5Y Avg
47.75%
Market Cap
$29.07B
EBITDA Margin
30.90%
TTM Avg
31.59%
3Y Avg
31.63%
5Y Avg
30.80%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.79B | 25.77% | 26.06% | 26.61% | 28.02% |
| Incyte Corporation (INCY)vs › | $24.48B | 27.93% | 16.21% | 17.95% | 14.24% |
| Moderna, Inc. (MRNA)vs › | $25.26B | -147.07% | -132.24% | -66.39% | -46.73% |
| Quest Diagnostics Incorporated (DGX)vs › | $26.24B | 19.69% | 19.16% | 18.89% | 21.02% |
| BioNTech SE (BNTX)vs › | $23.30B | -9.29% | -23.11% | 12.60% | 20.38% |
| Labcorp Holdings Inc. (LH)vs › | $26.53B | 15.75% | 14.53% | 14.10% | 17.90% |
| STERIS plc (STE)vs › | $23.06B | 26.76% | 25.68% | 26.35% | 25.75% |
| United Therapeutics Corporation (UTHR)vs › | $21.72B | 50.36% | 50.37% | 51.80% | 47.75% |
| Mettler-Toledo International Inc. (MTD)vs › | $29.07B | 30.90% | 31.59% | 31.63% | 30.80% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $29.97B | 15.00% | 4.83% | -18.55% | -52.26% |
Gross Margin
36.8%
EBITDA Margin
25.8%
Operating Margin
20.6%
Net Margin
17.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 25.77% |
| 2026-03-31 | 26.24% |
| 2025-12-31 | 25.29% |
| 2025-09-30 | 26.94% |
| 2025-06-30 | 26.05% |
| 2025-03-31 | 24.12% |
| 2024-12-31 | 28.23% |
| 2024-09-30 | 27.85% |
| 2024-06-30 | 24.17% |
| 2024-03-31 | 23.39% |
| 2023-12-31 | 28.21% |
| 2023-09-30 | 30.34% |
| 2023-06-30 | 29.36% |
| 2023-03-31 | 27.81% |
| 2022-12-31 | 27.23% |
| 2022-09-30 | 31.67% |
| 2022-06-30 | 32.92% |
| 2022-03-31 | 30.07% |
| 2021-12-31 | 29.53% |
| 2021-09-30 | 30.22% |
| 2021-06-30 | 32.97% |
| 2021-03-31 | 31.21% |
| 2020-12-31 | 25.99% |
| 2020-09-30 | 25.41% |
| 2020-06-30 | 25.51% |
| 2020-03-31 | 22.49% |
| 2019-12-31 | 22.04% |
| 2019-09-30 | 21.61% |
| 2019-06-30 | 22.13% |
| 2019-03-31 | 21.11% |
| 2018-12-31 | 26.83% |
| 2018-09-30 | 18.60% |
| 2018-06-30 | 17.89% |
| 2018-03-31 | 18.14% |
| 2017-12-31 | 20.43% |
| 2017-09-30 | 17.61% |
| 2017-06-30 | 19.48% |
| 2017-03-31 | 21.89% |
| 2016-12-31 | 20.09% |
| 2016-09-30 | 20.20% |
| 2016-06-30 | 21.62% |
| 2016-03-31 | 14.44% |
| 2015-12-31 | 19.04% |
| 2015-09-30 | 5.49% |
| 2015-06-30 | 17.04% |
| 2015-03-31 | 20.78% |
| 2014-12-31 | 19.04% |
| 2014-09-30 | 18.85% |
| 2014-06-30 | 20.93% |
| 2014-03-31 | 17.62% |
| 2013-12-31 | 17.22% |
| 2013-09-30 | 18.02% |
| 2013-06-30 | 18.35% |
| 2013-03-31 | 18.80% |
| 2012-12-31 | 16.08% |
| 2012-09-30 | 15.01% |
| 2012-06-30 | 16.75% |
| 2012-03-31 | 19.06% |
| 2011-12-31 | 15.37% |
| 2011-09-30 | 15.19% |
| 2011-06-30 | 15.30% |
| 2011-03-31 | 16.35% |
| 2010-12-31 | 9.18% |
| 2010-09-30 | 16.06% |
| 2010-06-30 | 17.10% |
| 2010-03-31 | 16.96% |
| 2009-12-31 | 13.63% |
| 2009-09-30 | 17.07% |
| 2009-06-30 | 17.28% |
| 2009-03-31 | 14.93% |
| 2008-12-31 | 16.67% |
| 2008-09-30 | 13.04% |
| 2008-08-05 | 20.69% |
| 2008-03-31 | 19.50% |
| 2007-12-31 | 8.59% |
| 2007-09-30 | 11.04% |
| 2007-06-30 | 18.66% |
| 2007-03-31 | 20.81% |
| 2006-12-31 | 14.96% |
| 2006-09-30 | 15.06% |
| 2006-06-30 | 18.78% |
| 2006-03-31 | 18.40% |
| 2005-12-31 | 16.66% |
| 2005-09-30 | 14.43% |
| 2005-06-30 | 17.75% |
| 2005-03-31 | 20.13% |
| 2004-12-31 | 20.06% |
| 2004-09-30 | 11.09% |
| 2004-06-30 | 14.70% |
| 2004-03-31 | 14.30% |
| 2003-12-31 | 30.78% |
| 2003-09-30 | 12.24% |
| 2003-06-30 | 15.27% |
| 2003-03-31 | 12.39% |
| 2002-12-31 | 14.99% |
| 2002-09-30 | 5.24% |
